Clopidogrel Pellets Manufacturer & Supplier
WHO-GMP compliant anti-platelet pellets supporting secondary prevention of atherothrombotic events. Built for consistent layering to maintain bioavailability in fixed-dose combinations.
Product overview
Clopidogrel is a trusted antiplatelet prodrug that helps prevent blood clots in patients with heart disease, stroke risk, or peripheral arterial conditions. Our pelletised form enhances manufacturability and bioavailability consistency—supporting both monotherapy capsules and fixed-dose combination tablets used in cardiology and post-angioplasty regimens.
Key characteristics
- Uniform Pellet Morphology: Ensures consistent dissolution and reproducible drug release across capsule and tablet formats.
- Stability Controlled Processing: Inline temperature and humidity mapping maintain clopidogrel integrity throughout granulation and coating.
- High Flowability: Narrow particle size distribution reduces segregation and improves capsule fill uniformity.
- Regulatory-Ready Documentation: Comparative dissolution profiles, nitrosamine risk assessments, and multi-pH dissolution data available.
- Compatibility: Ideal for co-formulation with aspirin, atorvastatin, or other cardioprotective APIs.
- Technical Support: Full assistance for gastro-resistant layering, lubricant optimization, and fill-weight adjustments during scale-up.
Technical information
- API: Clopidogrel Bisulfate
- Assay: 98.0–102.0%
- Pellet Size Range: 500–1000 μm (customizable)
- Loss on Drying: ≤1.5%
- Coating: Enteric or moisture-barrier optional
- Packaging: 25 kg moisture-barrier HDPE drums with tamper-evident liners
- Storage: Store below 25°C, protected from light and humidity.
Pharmaceutical applications
- Pharmaceutical manufacturers producing antiplatelet capsules or fixed-dose combinations.
- Contract formulators requiring consistent pellet-based DAPT products.
- Hospitals and B2B distributors sourcing bulk raw material for cardiovascular drug lines.
How it works
Clopidogrel acts by irreversibly blocking P2Y12 ADP receptors on platelets, reducing their ability to clump together and form clots. It is often prescribed after stent placement or heart attacks to reduce recurrent cardiovascular events. Pelletised clopidogrel ensures consistent absorption and reduced formulation variability, enhancing therapeutic reliability.
Usage note
For pharmaceutical manufacturing and educational purposes only. Patients should use clopidogrel-containing medicines strictly under medical supervision. Manufacturers should validate formulations in compliance with regional pharmacopeial and regulatory standards.
Product specifications
- Product
- Clopidogrel Pellets
- Form
- Pellets
- Therapeutic category
- Anti-Platelet
- Available strengths
- 40%, 45.45%, 50%, 60%, 45%
- Grade
- IP / BP / USP / EP
- Pack size
- 25/50 kg
- Site certifications
- WHO-GMP, ISO 9001, ISO 14001
Detailed specifications, COA and technical documentation are shared on request.
Supply and enquiries
Rraynex supplies Clopidogrel Pellets to pharmaceutical manufacturers, formulation developers and CDMOs in 25/50 kg packs with batch traceability. Send your quantity, grade and documentation needs through the enquiry form and the commercial team will reply with specifications and a quotation. Rraynex is a B2B supplier and does not sell to consumers.
Send product enquiry Browse all pellets Manufacturing capabilities
Other Clopidogrel products from Rraynex
- Clopidogrel + Domperidone — Granules
- Clopidogrel + Pantoprazole — Granules
- Clopidogrel DC — Granules
- Aspirin + Clopidogrel (WW) — Pellets
- Atorvastatin + Clopidogrel — Pellets
- Clopidogrel (WW) — Pellets
- Clopidogrel + Aspirin — Pellets